Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-[beta]2 microglobulin-null mice.
Glimm, H. 1; Eisterer, W. 1; Lee, K. 1; Cashman, J. 1; Holyoake, T. L. 1; Nicolini, F. 1; Shultz, L. D. 2; von Kalle, C. 3; Eaves, C. J. 1
[Miscellaneous Article] Journal of Clinical Investigation. 107(2):199-206, January 2001.

(Format: HTML)

Increasing use of purified or cultured human hematopoietic cells as transplants has revealed an urgent need for better methods to predict the speed and durability of their engraftment potential. We now show that NOD/SCID-[beta]2 microglobulin-null (NOD/SCID-[beta]2m-/-) mice are sequentially engrafted by two distinct and previously unrecognized populations of transplantable human short-term repopulating hematopoietic cells (STRCs), neither of which efficiently engraft NOD/SCID mice. One is predominantly CD34 CD38 and is myeloid-restricted; the other is predominantly CD34 CD38- and has broader lymphomyeloid differentiation potential. In contrast, the long-term repopulating human cells that generate lymphoid and myeloid progeny in NOD/SCID mice engraft and self-renew in NOD/SCID-[beta]2m-/- mice equally efficiently. In short-term expansion cultures of adult bone marrow cells, myeloid-restricted STRCs were preferentially amplified (greater than tenfold) and, interestingly, both types of STRC were found to be selectively elevated in mobilized peripheral blood harvests. These results suggest an enhanced sensitivity of STRCs to natural killer cell-mediated rejection. They also provide new in vivo assays for different types of human STRC that may help to predict the engraftment potential of clinical transplants and facilitate future investigation of early stages of human hematopoietic stem cell differentiation.

Copyright (C) 2001 The American Society for Clinical Investigation, Inc.